DeepIntent Celebrates Robust Year-Over-Year Growth as Healthcare Marketers Invest in Digital Channels, Particularly CTV

More than 600 pharmaceutical brands now use DeepIntent to simplify campaign planning, activation, measurement, and optimization

NEW YORK, Jan. 11, 2023 /PRNewswire/ — DeepIntent, the leading healthcare advertising technology company built to influence better patient health and business outcomes, today announced that it has reached a significant milestone, achieving growth for the fifth consecutive year and a triple-digit percentage growth rate across connected television (CTV) campaigns.

Adding more than 100 employees to its team in 2022, the company’s growth has outpaced growth in the broader healthcare advertising segment, as pharmaceutical marketers increasingly embrace digital advertising, particularly on CTV. In 2022, DeepIntent experienced triple-digit growth in CTV investment on its demand side platform, making CTV one of the fastest-growing channels for the hundreds of pharmaceutical brands now using the DeepIntent Healthcare Advertising Platform.


In the last year, DeepIntent has introduced many significant innovations that combine data and technology to enhance campaign effectiveness. Last May, DeepIntent became the first demand side platform to offer a patient reach guarantee, leveraging the patented technology of DeepIntent Outcomes™. Patient Reach Guarantee offers healthcare marketers unprecedented certainty that their advertising campaigns will reach verified patients, as defined by medical claims codes. DeepIntent also launched Patient Planner to unlock the power of healthcare data in a HIPAA-compliant way, giving advertisers the control and transparency needed to activate successful patient audiences and programmatic campaigns.

“As we enter our seventh year as a company, DeepIntent has become more than the DSP of choice for healthcare marketers. Building upon our capabilities for campaign planning, activation, measurement, and optimization, we’ve made a number of strategic investments to keep that momentum going as we continue to lead pharma into the future,” said Chris Paquette, Founder and CEO of DeepIntent. “DeepIntent is well-positioned to continue growing in 2023 and beyond as we pursue our long-term goal of using advertising technology to measurably improve the lives of patients.”

Additional milestones achieved by DeepIntent in 2022 include:

For more information about DeepIntent, visit

About DeepIntent

DeepIntent is leading the healthcare advertising industry with data-driven solutions built for the future. Built purposefully for healthcare marketers, DeepIntent’s platform is proven to drive higher audience quality and script performance. It enables marketers to plan, activate, measure, and optimize their campaigns all within a single platform. Conceived by former Memorial Sloan Kettering data scientists, DeepIntent empowers nine of the top ten pharmaceutical companies and the leading healthcare advertising agencies to improve patient outcomes through the artful use of advertising, data science, and real-world health data. For more information, visit or find us on Twitter, Facebook, or LinkedIn.

Press Contact
Finn Partners for DeepIntent
Mena Buscetto

Cision View original content to download multimedia:

SOURCE DeepIntent